Abstract

You have accessJournal of UrologyCME1 Apr 2023PD04-04 MOLECULAR CORRELATES WITH PSMA EXPRESSION IN PROSTATE CANCER Adam Weiner, Eric Li, JJ Zhang, Elai Davicioni, Edward Schaeffer, Ashley Ross, Luca Valle, Paul Boutros, Jeremie Calais, Amar Kishan, and Robert Reiter Adam WeinerAdam Weiner More articles by this author , Eric LiEric Li More articles by this author , JJ ZhangJJ Zhang More articles by this author , Elai DavicioniElai Davicioni More articles by this author , Edward SchaefferEdward Schaeffer More articles by this author , Ashley RossAshley Ross More articles by this author , Luca ValleLuca Valle More articles by this author , Paul BoutrosPaul Boutros More articles by this author , Jeremie CalaisJeremie Calais More articles by this author , Amar KishanAmar Kishan More articles by this author , and Robert ReiterRobert Reiter More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003228.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Not all prostate cancer (PCa) is detected by prostate-specific membrane antigen (PSMA)-based imaging or responsive to PSMA-based radiopharmaceuticals. We sought to define the molecular processes associated with PSMA expression. METHODS: Using multiple datasets (n=5 Homo sapiens; n=2 mouse xenograft models; n=1 cell line), we correlated PSMA gene expression (FOLH1) with biological processes and treatments. RESULTS: In an exploratory analysis of a prospective cohort of 7,000 tumors from radical prostatectomy, tumors with high PSMA RNA expression (one standard deviation above mean) tended to demonstrate more androgen receptor activity, high genomic risk scores (Decipher), more markers of homologous recombination deficiency, less immune content, lower predicted response to radiotherapy (“PORTOS”), and enrichment for P13K/AKT/mTOR pathways (Figure 1). In a validation cohort, adenocarcinoma tumors (n=49) expressed more PSMA than benign tissue (n=12; Wilcoxon p=0.020) and castration resistant tumors (n=27; p=0.015). An additional cohort showed adenocarcinoma (n=110) expressed more PSMA than neuroendocrine tumors (n=20; p=4.4e-6). In a mouse xenograft model (n=1) of high-grade adenocarcinoma, PSMA expression declined as the model underwent conversion to castration resistance and subsequent neuroendocrine transformation following castration. From both mouse and human data, treatment with androgen deprivation was associated with an initial increase in PSMA expression. From TCGA (n=491), tumors with high PSMA expression also tended to have a higher mutational burden and fewer tumor infiltrating lymphocytes in a subset with immunohistochemistry data (n=330). To assess the association between PSMA and P13K/AKT/mTOR, we used data from a cell line exposed to the MAPK inhibitor trametinib which upregulates P13K/AKT/mTOR pathways. VCaP cells treated with both enzalutamide and trametinib expressed two-fold more PSMA compared to those treated with the individual medications or neither. CONCLUSIONS: PCa with high PSMA expression is characterized by relevant differences in biological processes. If corroborated with PSMA-PET avidity, these results could optimize precision PCa care by informing adjunctive molecular testing or treatment paradigms for low or high PSMA expressing tumors. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e143 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Adam Weiner More articles by this author Eric Li More articles by this author JJ Zhang More articles by this author Elai Davicioni More articles by this author Edward Schaeffer More articles by this author Ashley Ross More articles by this author Luca Valle More articles by this author Paul Boutros More articles by this author Jeremie Calais More articles by this author Amar Kishan More articles by this author Robert Reiter More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call